vs
Side-by-side financial comparison of SunOpta Inc. (STKL) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
SunOpta Inc. is the larger business by last-quarter revenue ($205.4M vs $158.6M, roughly 1.3× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 0.4%, a 70.8% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 16.6%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $12.1M).
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
STKL vs STOK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $158.6M |
| Net Profit | $816.0K | $112.9M |
| Gross Margin | 12.4% | — |
| Operating Margin | 3.3% | 70.2% |
| Net Margin | 0.4% | 71.2% |
| Revenue YoY | 16.6% | 3661.1% |
| Net Profit YoY | 113.1% | 528.0% |
| EPS (diluted) | $0.01 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $205.4M | — | ||
| Q2 25 | $191.5M | — | ||
| Q1 25 | $201.6M | $158.6M | ||
| Q4 24 | $193.9M | $22.6M | ||
| Q3 24 | $175.9M | — | ||
| Q2 24 | $169.5M | — | ||
| Q1 24 | $184.4M | — | ||
| Q4 23 | $178.1M | — |
| Q3 25 | $816.0K | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $4.8M | $112.9M | ||
| Q4 24 | $-8.7M | $-10.5M | ||
| Q3 24 | $-6.2M | — | ||
| Q2 24 | $-5.3M | — | ||
| Q1 24 | $2.9M | — | ||
| Q4 23 | $-15.5M | — |
| Q3 25 | 12.4% | — | ||
| Q2 25 | 14.8% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 13.0% | — | ||
| Q2 24 | 12.5% | — | ||
| Q1 24 | 16.8% | — | ||
| Q4 23 | 14.1% | — |
| Q3 25 | 3.3% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | 5.2% | 70.2% | ||
| Q4 24 | 1.4% | -60.4% | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 5.5% | — | ||
| Q4 23 | 2.1% | — |
| Q3 25 | 0.4% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 2.4% | 71.2% | ||
| Q4 24 | -4.5% | -46.4% | ||
| Q3 24 | -3.5% | — | ||
| Q2 24 | -3.1% | — | ||
| Q1 24 | 1.6% | — | ||
| Q4 23 | -8.7% | — |
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.03 | — | ||
| Q1 25 | $0.04 | $1.90 | ||
| Q4 24 | $-0.08 | $-0.15 | ||
| Q3 24 | $-0.05 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $0.02 | — | ||
| Q4 23 | $-0.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.2M | $274.8M |
| Total DebtLower is stronger | $250.8M | — |
| Stockholders' EquityBook value | $162.8M | $350.1M |
| Total Assets | $694.1M | $406.9M |
| Debt / EquityLower = less leverage | 1.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $2.2M | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $2.3M | $274.8M | ||
| Q4 24 | $1.6M | $128.0M | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $3.2M | — | ||
| Q1 24 | $1.5M | — | ||
| Q4 23 | $306.0K | — |
| Q3 25 | $250.8M | — | ||
| Q2 25 | $263.3M | — | ||
| Q1 25 | $260.6M | — | ||
| Q4 24 | $265.2M | — | ||
| Q3 24 | $289.9M | — | ||
| Q2 24 | $303.1M | — | ||
| Q1 24 | $258.8M | — | ||
| Q4 23 | $263.5M | — |
| Q3 25 | $162.8M | — | ||
| Q2 25 | $159.8M | — | ||
| Q1 25 | $154.8M | $350.1M | ||
| Q4 24 | $148.6M | $229.0M | ||
| Q3 24 | $155.0M | — | ||
| Q2 24 | $158.8M | — | ||
| Q1 24 | $163.6M | — | ||
| Q4 23 | $156.3M | — |
| Q3 25 | $694.1M | — | ||
| Q2 25 | $704.9M | — | ||
| Q1 25 | $690.7M | $406.9M | ||
| Q4 24 | $668.5M | $271.6M | ||
| Q3 24 | $699.3M | — | ||
| Q2 24 | $704.7M | — | ||
| Q1 24 | $671.8M | — | ||
| Q4 23 | $667.2M | — |
| Q3 25 | 1.54× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.68× | — | ||
| Q4 24 | 1.78× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.91× | — | ||
| Q1 24 | 1.58× | — | ||
| Q4 23 | 1.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $131.8M |
| Free Cash FlowOCF − Capex | $12.1M | $131.7M |
| FCF MarginFCF / Revenue | 5.9% | 83.0% |
| Capex IntensityCapex / Revenue | 2.1% | 0.1% |
| Cash ConversionOCF / Net Profit | 20.03× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $36.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $16.3M | — | ||
| Q2 25 | $-4.5M | — | ||
| Q1 25 | $22.3M | $131.8M | ||
| Q4 24 | $33.1M | $-23.2M | ||
| Q3 24 | $17.2M | — | ||
| Q2 24 | $-5.6M | — | ||
| Q1 24 | $5.3M | — | ||
| Q4 23 | $4.4M | — |
| Q3 25 | $12.1M | — | ||
| Q2 25 | $-9.2M | — | ||
| Q1 25 | $9.5M | $131.7M | ||
| Q4 24 | $24.0M | $-23.2M | ||
| Q3 24 | $11.7M | — | ||
| Q2 24 | $-15.3M | — | ||
| Q1 24 | $-2.3M | — | ||
| Q4 23 | $-3.5M | — |
| Q3 25 | 5.9% | — | ||
| Q2 25 | -4.8% | — | ||
| Q1 25 | 4.7% | 83.0% | ||
| Q4 24 | 12.4% | -102.7% | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | -9.0% | — | ||
| Q1 24 | -1.2% | — | ||
| Q4 23 | -2.0% | — |
| Q3 25 | 2.1% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 6.3% | 0.1% | ||
| Q4 24 | 4.7% | 0.2% | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 5.7% | — | ||
| Q1 24 | 4.1% | — | ||
| Q4 23 | 4.5% | — |
| Q3 25 | 20.03× | — | ||
| Q2 25 | -1.03× | — | ||
| Q1 25 | 4.63× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.83× | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
STOK
Segment breakdown not available.
